中文

ST任子行 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥0.05B+2.0%
Gross profit¥0.03B
Operating income¥-0.03B
Net income¥-0.03B
Gross margin62.2%Net margin -50.9%
Revenue Q/Q-82.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.02B37.8%
R&D¥0.03B58.6%
SG&A¥0.04B70.9%
Tax & other¥-0.00B-0.1%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

天山生物戴维医疗掌趣科技珈伟新能博晖创新麦捷科技海达股份同大股份硕贝德华灿光电旋极信息ST凯利

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies